Nivolumab与多西紫杉醇在晚期肺鳞癌患者中的疗效比较被引量：11

Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small Cell Lung Cancer

下载PDF

导出

摘要 1文献来源 Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus Docetaxel in advanced squamouscell non-small-cell lung cancer[J].N Engl J Med,2015,373（2）：123-135. 2证据水平 1b。 3背景晚期肺鳞癌患者一线化疗疾病进展后,可选择的治疗方案有限。其中以多西紫杉醇化疗应用最广，一直被认为是晚期肺鳞癌二线治疗的最有效方案。

作者陆舜虞永峰张一辰

机构地区上海交通大学附属胸科医院广东省人民医院肿瘤中心

出处《循证医学》 CSCD 2015年第4期225-227,231,共4页 The Journal of Evidence-Based Medicine

关键词晚期肺鳞癌 Nivolumab 多西紫杉醇疗效 advanced squamous-cell lung cancer Nivolumab Docetaxel efficacy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer(CheckMate 063): A phase 2, single-arm trial[J]. Lancet Oncol, 2015,16(3):257-265.
2FDA expands approved use of Opdivo to treat lung cancer. Press release of the Food and Drug Administration, Bethesda, MD, March 4, 2015. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm436534.htm.
3Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014,515(7528):563-567.

同被引文献21

1Price TJ,Peeters M,Kim TW.ASPECCT研究:帕尼单抗的疗效与西妥昔单抗相当[J].中华结直肠疾病电子杂志,2014,3(2):6-6. 被引量：17
2Dean G Tang.Understanding cancer stem cell heterogeneity and plasticity[J].Cell Research,2012,22(3):457-472. 被引量：37
3A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis[J].Science Foundation in China,2014,22(2):22-22. 被引量：42
4屈若祎,周宝森.2004-2010年中国肺癌死亡分布及趋势分析[J].中国卫生统计,2014,31(6):932-935. 被引量：67
5董忠谊,钟文昭.克隆源性肿瘤新抗原诱导T细胞免疫反应增强免疫检查点抑制剂疗效[J].循证医学,2016,16(2):67-67. 被引量：6
6Armel Herve Nwabo Kamdje,Paul Takam Kamga,Richard Tagne Simo,Lorella Vecchio,Paul Faustin Seke Etet,Jean Marc Muller,Giulio Bassi,Erique Lukong,Raghuveera Kumar Goel,Jeremie Mbo Amvene,Mauro Krampera.Developmental pathways associated with cancer metastasis:Notch,Wnt,and Hedgehog[J].Cancer Biology & Medicine,2017,14(2):109-120. 被引量：11
7Yi Yang,Chia-Wei Li,Li-Chuan Chan,Yongkun Wei,Jung-Mao Hsu,Weiya Xia,Jong-Ho Cha,Junwei Hou,Jennifer L. Hsu,Linlin Sun,Mien-Chie Hung.Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth[J].Cell Research,2018,28(8):862-864. 被引量：42
8Rui-Hua Xu,Lin Shen,Ke-Ming Wang,Gang Wu,Chun-Mei Shi,Ke-Feng Ding,Li-Zhu Lin,Jin-Wan Wang,Jian-Ping Xiong,Chang-Ping Wu,Jin Li,Yun-Peng Liu,Dong Wang,Yi Ba,Jue-Ping Feng,Yu-Xian Bai,Jing-Wang Bi,Li-Wen Ma,Jian Lei,Qing Yang,Hao Yu.Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer:a multicenter,randomized,double-blinded,placebo-controlled,phaseⅡclinical trial[J].Chinese Journal of Cancer,2017,36(12):677-685. 被引量：4
9Ankita Tiwari,Shivani Saraf,Amit Verma,Pritish Kumar Panda,Sanjay K Jain.Novel targeting approaches and signaling pathways of colorectal cancer: An insight[J].World Journal of Gastroenterology,2018,24(39):4428-4435. 被引量：6
10Joseph Tintelnot,Alexander Stein.Immunotherapy in colorectal cancer: Available clinical evidence,challenges and novel approaches[J].World Journal of Gastroenterology,2019,25(29):3920-3928. 被引量：6

引证文献11

1李雅楠.19例晚期非小细胞肺癌Nivolumab治疗的观察与护理[J].天津护理,2017,25(1):54-55.
2Fei Zhou,Meng Qiao,Caicun Zhou.The cutting-edge progress of immune-checkpoint blockade in lung cancer[J].Cellular & Molecular Immunology,2021,18(2):279-293. 被引量：24
3Laura Strauss,Valentina Guarneri,Alessandra Gennari,Antonio Sica.Implications of metabolism-driven myeloid dysfunctions in cancer therapy[J].Cellular & Molecular Immunology,2021,18(4):829-841. 被引量：1
4Xiaolei Li,Wenhui Song,Changshun Shao,Yufang Shi,Weidong Han.Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy[J].Cellular & Molecular Immunology,2019,16(1):28-39. 被引量：5
5Yan Zou,Jingjing Wei,Yifeng Xia,Fenghua Meng,Jiandong Yuan,Zhiyuan Zhong.Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin[J].Signal Transduction and Targeted Therapy,2018,3(1):11-18. 被引量：2
6Min Yuan,Li-Li Huang,Jian-Hua Chen,Jie Wu,Qing Xu.The emerging treatment landscape of targeted therapy in non-small-cell lung cancer[J].Signal Transduction and Targeted Therapy,2019,4(1):49-62. 被引量：19
7Siyuan Qin,Jingwen Jiang,Yi Lu,Edouard CNice,Canhua Huang,Jian Zhang,Weifeng He.Emerging role of tumor cell plasticity in modifying therapeutic response[J].Signal Transduction and Targeted Therapy,2020,5(1):549-584. 被引量：8
8Yuan-Hong Xie,Ying-Xuan Chen,Jing-Yuan Fang.Comprehensive review of targeted therapy for colorectal cancer[J].Signal Transduction and Targeted Therapy,2020,5(1):2155-2184. 被引量：41
9Tao Jiang,Pingyang Wang,Jie Zhang,Yanqiu Zhao,Jianying Zhou,Yun Fan,Yongqian Shu,Xiaoqing Liu,Helong Zhang,Jianxing He,Guanghui Gao,Xiaoqian Mu,Zhang Bao,Yanjun Xu,Renhua Guo,Hong Wang,Lin Deng,Ningqiang Ma,Yalei Zhang,Hui Feng,Sheng Yao,Jiarui Wu,Luonan Chen,Caicun Zhou,Shengxiang Ren.Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC:a multicenter phase-II trial[J].Signal Transduction and Targeted Therapy,2021,6(11):3295-3303. 被引量：12
10Lamei Huang,Zhixing Guo,Fang Wang,Liwu Fu.KRAS mutation:from undruggable to druggable in cancer[J].Signal Transduction and Targeted Therapy,2021,6(12):3466-3485. 被引量：9

二级引证文献121

1张清伟,许毅娇,杨舒雯,陈志盛,肖雄.年龄校正查尔森合并症指数用于评估晚期非小细胞肺癌患者免疫治疗预后的价值[J].中国校医,2023,37(12):919-924.
2杨小冬,张桂芳,慕竹青,孟娜娜.呋喹替尼治疗晚期结直肠癌起始剂量和疗效及不良反应探讨[J].社区医学杂志,2022,20(17):967-972. 被引量：1
3马成才,周英,许天齐,吴宾,宋立强,张艰.免疫治疗6周后中性粒细胞淋巴细胞比率及乳酸脱氢酶对非小细胞肺癌预后预测价值[J].临床军医杂志,2022,50(3):246-250. 被引量：4
4彭杨,马代远.免疫检查点抑制剂联合低剂量照射治疗非小细胞肺癌研究进展[J].肿瘤研究与临床,2023,35(2):147-150.
5Kaifeng He,Su Zeng,Linghui Qian.Recent progress in the molecular imaging of therapeutic monoclonal antibodies[J].Journal of Pharmaceutical Analysis,2020,10(5):397-413. 被引量：2
6简小兰,曾普华,杜佳,何凤姣,李克雄,蒋益兰.健脾消癌方对结肠癌HCT116细胞迁移、侵袭的影响研究[J].中医学报,2021,36(1):132-137. 被引量：9
7Jing Chen,Hong-Wei Sun,Yan-Yan Yang,Hai-Tian Chen,Xing Juan Yu,Wen Chao Wu,Yi-Tuo Xu,LiLian Jin,Xiao-Jun Wu,Jing Xu,Limin Zheng.Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer[J].Signal Transduction and Targeted Therapy,2021,6(2):447-460. 被引量：4
8高雅媚,王斌,王亚梅,贾漪涛.曲氟尿苷替匹嘧啶联合贝伐珠单抗治疗难治性转移性结直肠癌的疗效与安全性的meta分析[J].消化肿瘤杂志（电子版）,2021,13(1):59-65. 被引量：1
9Chaoyue Su,Jianye Zhang,Yosef Yarden,Liwu Fu.The key roles of cancer stem cell-derived extracellular vesicles[J].Signal Transduction and Targeted Therapy,2021,6(4):1142-1156. 被引量：1
10Zeyu Wang,Hao Zhang,Shengchao Xu,Zhixiong Liu,Quan Cheng.The adaptive transition of glioblastoma stem cells and its implications on treatments[J].Signal Transduction and Targeted Therapy,2021,6(4):1199-1211. 被引量：3

1王洁,黄玲.吉非替尼与标准化疗对EGFR突变的晚期非小细胞肺癌患者疗效和安全性的比较[J].循证医学,2011,11(1):25-27. 被引量：4
2刘艳,刘殊,许崇安.参一胶囊辅助化疗治疗晚期非小细胞肺癌临床观察[J].山西医药杂志,2007,36(6):554-556. 被引量：7
3崔艳艳,綦会霞.伊立替康联合替吉奥二线治疗晚期胃癌临床观察[J].肿瘤基础与临床,2016,29(6):498-500. 被引量：6
4王彬,汤雷,聂国庆,张超.替吉奥联合多西他赛、顺铂治疗晚期胃癌的临床观察[J].现代肿瘤医学,2013,21(9):2049-2051. 被引量：8
5胡传杏子.以泰素帝为主联合化疗治疗晚期乳腺癌87例临床观察[J].临床急诊杂志,2007,8(6):358-359. 被引量：1
6菲琳.Docetaxel与阿霉素联用不会增加心脏病的危险[J].国外医学情报,2000,21(7):37-37.
7丁春杰,杨磊.参芪扶正注射液对晚期非小细胞肺癌化疗患者免疫功能的影响[J].西部中医药,2012,25(1):7-9. 被引量：50
8沈彦,周颖,赵敏,魏艳芹.E-cadherin、CD44V6和HIF-1α在结肠癌组织中表达的意义[J].河北医药,2013,35(13):1931-1933. 被引量：1
9董粉英,刘洪,庞伟,梁金花.长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌[J].实用医学杂志,2008,24(1):100-101. 被引量：1
10刘俊彦,王哲海,郭珺,刘利妍.晚期三阴性乳腺癌的临床病理特征及预后分析[J].实用医学杂志,2013,29(3):429-431. 被引量：6

循证医学

2015年第4期

浏览历史

内容加载中请稍等...

Nivolumab与多西紫杉醇在晚期肺鳞癌患者中的疗效比较被引量：11

参考文献3

同被引文献21

引证文献11

二级引证文献121

相关作者

相关机构

相关主题

浏览历史

Nivolumab与多西紫杉醇在晚期肺鳞癌患者中的疗效比较 被引量：11

参考文献3

同被引文献21

引证文献11

二级引证文献121

相关作者

相关机构

相关主题

浏览历史

Nivolumab与多西紫杉醇在晚期肺鳞癌患者中的疗效比较被引量：11